Beijing GoBroad Hospital
Lymphoma & Myeloma Department
Research-oriented institution in Changping Life Science Park. Specialising in CAR-T cell immunotherapy, haematopoietic stem cell transplantation, and targeted therapy for relapsed/refractory haematological malignancies.
A Specialist Cancer Centre Built Around CAR-T Innovation
Beijing GoBroad Hospital (北京高博医院) opened in July 2023 as a specialist oncology hospital within Zhongguancun Life Science Park, Changping District, Beijing. The hospital was conceived as a translational medicine platform, bridging laboratory CAR-T research with clinical application for patients who have exhausted conventional treatment options.
The Lymphoma and Myeloma Department currently operates 77 inpatient beds with a dedicated CAR-T cell therapy ward. The hospital was designated for Beijing Basic Medical Insurance reimbursement in February 2024, making it one of the few private specialist centres in the city where domestic patients can access insurance-covered CAR-T cell therapy.
International patients receive care in private single-occupancy wards equipped with private bathrooms, refrigerator, and microwave. A dedicated international patient coordinator handles translation, visa support, airport transfers, and Zoom consultation scheduling with Dr. Hu prior to arrival.
The Lymphoma and Myeloma Department team, Zhongguancun Life Science Park, Beijing.
Dr. Kai Hu (胡凯), Beijing GoBroad Hospital
Dr. Kai Hu holds a PhD in Haematology from Peking University Health Science Center and has accumulated more than 20 years of experience in the diagnosis and treatment of haematological malignancies. His team has completed over 1,000 immunotherapy cases, making it one of the most experienced CAR-T programmes in northern China.
Dr. Hu pioneered two clinically significant protocols at GoBroad: sequential dual-target CAR-T therapy for multiply-relapsed diffuse large B-cell lymphoma (DLBCL), and combined CAR-T plus autologous stem cell transplantation (CAR-T + ASCT) for high-risk multiple myeloma. Both protocols address patient populations for whom single-target CAR-T and standard salvage regimens have failed.
His research output includes more than 20 peer-reviewed SCI publications. He presents regularly at the American Society of Hematology (ASH) Annual Meeting, the European Hematology Association (EHA) Congress, and the European Bone Marrow Transplantation (EBMT) meeting.
CAR-T Therapy Portfolio
GoBroad's Lymphoma and Myeloma Department operates one of the most comprehensive CAR-T antigen target portfolios in China. The team covers established single-target constructs (CD19, CD22, BCMA) as well as next-generation dual-target combinations (CD19&CD22, CD20&CD22, BCMA&GPRC5D) not yet routinely available at most transplant centres. Targets span six disease categories plus autoimmune diseases.
Patients who came to Dr. Hu's team from abroad
The following cases are drawn from patients treated by Dr. Kai Hu's team at Beijing GoBroad Hospital. Names and identifying details have been anonymised at the patients' request.
After transformation from follicular to DLBCL, this patient had exhausted standard salvage options in Russia before being referred to Dr. Hu's team. Following CD19 CAR-T therapy, the patient achieved a durable complete response and returned to normal daily life.
This patient had relapsed after both chemotherapy and an autologous transplant, with mediastinal disease complicating further treatment. The CD20/CD22 dual-target construct was selected to reduce the risk of antigen escape. One year after CAR-T infusion, the patient remains in complete remission and has returned to fitness training and outdoor activities.
After more than five years living with multiple myeloma and multiple relapses, physicians in Kazakhstan recommended only palliative management. This patient's family identified Dr. Hu's programme through an online search and contacted GoBroad directly. Two cycles of cytoreductive chemotherapy were followed by CAR-T cell infusion.
Omar arrived at GoBroad at age 27 as a medical doctoral student in Morocco, having failed six cycles of standard chemotherapy. Pre-existing epilepsy added complexity to the treatment protocol. The team performed tumour debulking surgery before infusing a CD19/CD20 dual-target CAR-T construct, achieving complete remission.
How to Access Treatment at Beijing GoBroad Hospital
The hospital has a defined intake pathway for international patients. China Care coordinates steps 1 through 5 on your behalf, acting as your interface with the GoBroad team throughout.
Gather your complete medical records: pathology reports, imaging (CT/PET-CT/MRI), treatment history, and current medications. Send these directly to the hospital's international patient team, or submit to China Care and we will forward them with a case summary in Chinese. The team reviews records within 2–3 working days.
records review · 2–3 daysThe Lymphoma and Myeloma Department will issue a preliminary treatment recommendation and itemised cost estimate based on your records. This includes planned CAR-T target, expected bridging therapy, hospitalisation duration, and facility fees. China Care translates and explains every line item.
written estimate providedBefore committing to travel, patients and families can conduct a direct video consultation with Dr. Hu via Zoom. China Care provides a simultaneous interpreter. This session covers your diagnosis, the proposed protocol, the manufacturing timeline, and any questions about procedure-specific risks or alternatives.
zoom · interpreter providedThe hospital provides an official invitation letter required for a medical visa application. China Care handles the visa support documentation for you and your accompanying family member. On arrival at Beijing Capital International Airport or Beijing Daxing Airport, a GoBroad driver meets you at the arrivals hall. Patients are admitted to a private international ward with private bathroom, refrigerator, and microwave. Dietary requirements including halal, kosher, and vegetarian meals can be pre-arranged.
visa invitation letter providedUpon discharge, the hospital provides a full English-language discharge summary including laboratory results, imaging, and follow-up instructions. Dr. Hu's team conducts remote monitoring appointments via Zoom at 1, 3, 6, and 12 months post-infusion. China Care remains available as an intermediary for any clinical questions between scheduled follow-ups.
remote monitoring · 12 monthsWhat patients ask about GoBroad.
What makes GoBroad different from other CAR-T centres in China?
Can international patients access clinical trials at GoBroad?
How long is the typical stay for CAR-T treatment?
What languages does the team speak?
Is travel insurance accepted? What about payment arrangements?
What follow-up does GoBroad provide after I return home?
Ready to enquire about treatment at GoBroad?
Submit your medical records through China Care and we will coordinate an initial review by Dr. Hu's team, typically within 2–3 working days.
China Care coordinates your case with Beijing GoBroad Hospital. We handle pre-admission documentation, translation, and on-the-ground support throughout your stay.
